| Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis L Richeldi, RM Du Bois, G Raghu, A Azuma, KK Brown, U Costabel, ... New England Journal of Medicine 370 (22), 2071-2082, 2014 | 3927 | 2014 |
| Interstitial lung disease in systemic sclerosis: a simple staging system NSL Goh, SR Desai, S Veeraraghavan, DM Hansell, SJ Copley, ... American journal of respiratory and critical care medicine 177 (11), 1248-1254, 2008 | 1128 | 2008 |
| Nintedanib for systemic sclerosis–associated interstitial lung disease O Distler, KB Highland, M Gahlemann, A Azuma, A Fischer, MD Mayes, ... New England Journal of Medicine 380 (26), 2518-2528, 2019 | 1089 | 2019 |
| Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report HR Collard, CJ Ryerson, TJ Corte, G Jenkins, Y Kondoh, DJ Lederer, ... American journal of respiratory and critical care medicine 194 (3), 265-275, 2016 | 1081 | 2016 |
| Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis TE Fingerlin, E Murphy, W Zhang, AL Peljto, KK Brown, MP Steele, ... Nature genetics 45 (6), 613-620, 2013 | 731 | 2013 |
| Pulmonary fibrosis secondary to COVID-19: a call to arms? P Spagnolo, E Balestro, S Aliberti, E Cocconcelli, D Biondini, ... The Lancet Respiratory Medicine 8 (8), 750-752, 2020 | 508 | 2020 |
| The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis PL Molyneaux, MJ Cox, SAG Willis-Owen, P Mallia, KE Russell, ... American journal of respiratory and critical care medicine 190 (8), 906-913, 2014 | 483 | 2014 |
| Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline G Raghu, M Remy-Jardin, L Richeldi, CC Thomson, Y Inoue, T Johkoh, ... American Journal of Respiratory and Critical Care Medicine 205 (9), e18-e47, 2022 | 458 | 2022 |
| Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial TM Maher, TJ Corte, A Fischer, M Kreuter, DJ Lederer, M Molina-Molina, ... The lancet Respiratory medicine 8 (2), 147-157, 2020 | 432 | 2020 |
| Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? TM Maher, AU Wells, GJ Laurent European Respiratory Journal 30 (5), 835-839, 2007 | 400 | 2007 |
| Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury CJ Scotton, MA Krupiczojc, M Königshoff, PF Mercer, YCG Lee, ... The Journal of clinical investigation 119 (9), 2550-2563, 2009 | 351 | 2009 |
| Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes TL Reddy, M Tominaga, DM Hansell, J von der Thusen, D Rassl, ... European Respiratory Journal 40 (2), 377-385, 2012 | 349 | 2012 |
| Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised … AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, ... The lancet Respiratory medicine 8 (5), 453-460, 2020 | 347 | 2020 |
| Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study RG Jenkins, JK Simpson, G Saini, JH Bentley, AM Russell, R Braybrooke, ... The lancet Respiratory medicine 3 (6), 462-472, 2015 | 282 | 2015 |
| Rituximab in severe, treatment‐refractory interstitial lung disease GJ Keir, TM Maher, D Ming, R Abdullah, A de Lauretis, ... Respirology 19 (3), 353-359, 2014 | 278 | 2014 |
| Short‐term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis NS Goh, RK Hoyles, CP Denton, DM Hansell, EA Renzoni, TM Maher, ... Arthritis & rheumatology 69 (8), 1670-1678, 2017 | 271 | 2017 |
| Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease? AJ Byrne, TM Maher, CM Lloyd Trends in molecular medicine 22 (4), 303-316, 2016 | 262 | 2016 |
| Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis A De Lauretis, P Sestini, P Pantelidis, R Hoyles, DM Hansell, NSL Goh, ... The Journal of rheumatology 40 (4), 435-446, 2013 | 250 | 2013 |
| Lysophosphatidic acid induces αvβ6 integrin-mediated TGF-β activation via the LPA2 receptor and the small G protein Gαq MY Xu, J Porte, AJ Knox, PH Weinreb, TM Maher, SM Violette, ... The American journal of pathology 174 (4), 1264-1279, 2009 | 237 | 2009 |
| Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume M Kolb, L Richeldi, J Behr, TM Maher, W Tang, S Stowasser, C Hallmann, ... Thorax 72 (4), 340-346, 2017 | 236 | 2017 |
Athol U WellsProfessor of Respiratory Medicine, Imperial College,在 rbht.nhs.uk 的电子邮件经过验证
